SS Innovations International, Inc. reported unaudited financial results for the fourth quarter and full year ended December 31, 2025, showing substantial growth in revenue, installations, and surgical procedures. The company's performance highlights its expanding role in making surgical robotics more affordable and accessible globally, with particular significance for healthcare systems in emerging markets and underserved regions.
For the full year 2025, revenue increased 105.7% to $42.5 million from $20.6 million in 2024, while gross profit rose 131.2% to $19.5 million. The company installed 103 SSi Mantra surgical robotic systems during the year, representing a 119.1% increase from 2024. As of December 31, 2025, the cumulative installed base reached 168 systems across ten countries, with 7,885 cumulative surgeries performed, including 120 telesurgeries, 390 cardiac procedures, and 121 pediatric surgeries.
Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations, stated that the company gained significant market share in India's surgical robotics market during 2025 while expanding into new global geographies. The company progressed along regulatory pathways required for entering the United States and European Union markets, with anticipation that the U.S. Food and Drug Administration will complete its review of the 510(k) premarket notification for the SSi Mantra by mid-2026. The company also expects to obtain European Union CE marking certification this year.
The financial results demonstrate SS Innovations' growing impact on global healthcare accessibility. The company's focus on cost-effective robotic surgery solutions addresses a critical need in markets where advanced surgical technology has traditionally been prohibitively expensive. The expansion into cardiac and pediatric procedures, along with telesurgery capabilities, represents important advancements in specialized surgical care availability.
In the fourth quarter of 2025, revenue increased 79.1% to $14.5 million, with SSi Mantra installations totaling 40 systems, up 81.8% from the same period in 2024. The company continued to pioneer robotic telesurgery, completing the first telesurgery with the SSi Mantra Tele Surgeon Console on November 6, 2025. On December 5, 2025, the company submitted its 510(k) premarket notification to the FDA covering multiple surgical indications including general, urological, colorectal, gynecological and cardiac surgeries.
Subsequent to year-end, the company completed a private placement generating approximately $18.6 million in gross proceeds to support growth initiatives. Dr. Srivastava noted that this financing brings new long-term institutional investors and reflects strong insider confidence in the company's future. The funds are aimed at fueling SS Innovations' growth in 2026 and beyond as the company prepares for market entry into the United States and European Union.
The company's technological advancements include the development of five new 5-millimeter surgical instruments announced on January 6, 2026, for clinical use across multiple specialties including pediatric, cardiac, and head and neck surgery. These developments address procedures involving smaller anatomical structures, expanding the system's clinical applications.
SS Innovations' progress represents a significant development in global healthcare technology accessibility. As surgical robotics traditionally dominated by high-cost systems, the company's affordable alternatives could democratize access to minimally invasive surgical techniques worldwide. The expansion into cardiac and pediatric specialties addresses critical gaps in robotic surgical capabilities, while telesurgery innovations could potentially extend expert surgical care to remote locations. The company's regulatory progress toward U.S. and European markets indicates growing recognition of its technology's capabilities and safety profile.
More information about the company is available at https://ssinnovations.com. Additional updates relating to SS Innovations are available in the company's newsroom at https://tinyurl.com/ssiinewsroom.
